Stephen J. Schuster

32.8k citations

366 papers · 11.7k indexed · 3 hit papers · h-index 48

Impact in

Oncology top 0.1%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment

Papers in

Pathology and Forensic Medicine 212
- Lymphoma Diagnosis and Treatment 212
Genetics 117
- Chronic Lymphocytic Leukemia Research 109

Co-authors: Jakub Svoboda Sunita D. Nasta Elise A. Chong Daniel J. Landsburg Edward A. Stadtmauer David L. Porter Donald E. Tsai Carl H. June
Journals: Blood (123 papers)Journal of Clinical Oncology (39 papers)American Journal of Hematology (16 papers)Blood Advances (15 papers)Hematological Oncology (12 papers)
Partner nations: United States Australia Germany

In The Last Decade

Stephen J. Schuster

348 papers receiving 11.5k citations

Hit Papers

align trajectories log scale

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study 2022 · 244 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 The Lancet Oncology
2017 New England Journal of Medicine
2014 New England Journal of Medicine

Peers

Countries citing papers authored by Stephen J. Schuster

Since Specialization

Citations

This map shows the geographic impact of Stephen J. Schuster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen J. Schuster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen J. Schuster more than expected).

Fields of papers citing papers by Stephen J. Schuster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen J. Schuster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen J. Schuster. The network helps show where Stephen J. Schuster may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Stephen J. Schuster, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen J. Schuster Line = papers co-authored together Stephen J. Schuster links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome JAMA Dermatology ·И. В. Мединцов, Jonathan Sussman, BP Norge, Colin Thomas, Shaoxiong Yao, Daniel J. Landsburg, Jakub Svoboda, Ellen Kim, Alain H. Rook, Jina Chung, John P. Plastaras, Michael J. LaRiviere, Harper Hubbeling, Monica Chelius, Sunita D. Nasta, Elise A. Chong, Stephen J. Schuster, Stefan K. Barta	2025	0
2	Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II Blood ·Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung Soo Yoon, Keith Fay, Georg Heß, Martin Dreyling, Norma C. Gutiérrez, 崔平潤, Antonia Kwan, Elicia Penuel, Samuel Tracy, Dóra Szobonya, Bae Minjae, Volker Wiebking, Michael C. Wei, Lihua E. Budde	2024	4
3	Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study Journal of Clinical Oncology ·Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung‐Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Chan Y. Cheah, G Hupkes, Huang Huang, Antonia Kwan, Michael C. Wei, Shen Yin, Nancy L. Bartlett	2024	34
4	Senza5 TM CART5: An Autologous CD5-Deleted Anti-CD5 CART Product with Enhanced Anti-T-Cell Lymphoma Activity Blood ·Adam E. Snook, Yuri Huillca Aedo, Guido Ghilardi, A Fernández, Steven Yang, Taneli Saastamoinen, Patrizia Porazzi, Rosemary Mazanet, Stephen J. Schuster, Stefan K. Barta, Moises Carpio, Marco Ruella, М.С. Чернов	2023	1
5	DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study American Journal of Hematology ·Scott F. Huntington, Stephen J. Schuster, Wei Ding, Amber B. Koehler, Danielle M. Brander, Allison Rosenthal, José F. Leis, Han W. Tun, Muhamad Alhaj Moustafa, Madiha Iqbal, Wei He, Albert S. Kearney, Ziliang Zhong, Min Gui, Anthony R. Mato	2023	7
6	Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy Clinical and Translational Radiation Oncology ·Nikhil Yegya‐Raman, Christopher M. Wright, Michael J. LaRiviere, Jonathan Baron, Daniel Y. Lee, Daniel J. Landsburg, Jakub Svoboda, Sunita D. Nasta, James N. Gerson, Stefan K. Barta, Elise A. Chong, Stephen J. Schuster, Amit Maity, Andrea Facciabene, Ima Paydar, John P. Plastaras	2023	4
7	Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells Transplantation and Cellular Therapy ·Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, James N. Gerson, Stephen J. Schuster, Stefan K. Barta, Elise A. Chong, Ivânia Silva Cornélio da Silva, Elizabeth Weber, Norma Livingstone, SusanM. Strickler, Alfred L. Garfall, Edward A. Stadtmauer, Noelle V. Frey, David L. Porter	2023	3
8	Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T‐Cell Lymphoma Dermatologic Therapy ·Jieming Hou, Supriya Rastogi, Daniel J. Lewis, Leah Cohen, Sara Choi, Carmela C. Vittorio, Paul Haun, Sara Samimi, ديما محمد نذير الحمصي, Rahul S. Bhansali, Elise A. Chong, Daniel J. Landsburg, Sunita D. Nasta, Stephen J. Schuster, Jakub Svoboda, Ellen J. Kim, Alain H. Rook, Stefan K. Barta	2023	2
9	TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones Blood Advances ·Lauren Shaw, Mathilde Poussin, Alba Rodríguez-García, Joshua T. Eggold, Nicholas G. Minutolo, E. Okpala, Alain H. Rook, Stephen J. Schuster, Daniel J. Powell	2022	5
10	Comparative Efficacy and Safety of Tisagenlecleucel (tisa-cel) and Axicabtagene Ciloleucel (axi-cel) in Relapsed/ Refractory Follicular Lymphoma (r/r FL) Transplantation and Cellular Therapy ·Michael Dickinson, Joaquín Martínez‐López, Arezoo Avid, R. S. Belscher, Hongbo Yang, M. A. Hovhannisyan, Teruhisa Ando, Flor de Maria Araújo Mendonça Silva, Dr Prof. Gokul Ch Das, Chiara Lobetti‐Bodoni, Stephen J. Schuster, Nathan Fowler	2022	1
11	Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma Blood Advances ·Gilles Salles, Stephen J. Schuster, Martin Dreyling, 信夫小笠原, John Kuruvilla, Piers Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jiménez Ubieto, Keith L. Davis, Grigor'eva Sk, Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thiéblemont, Nathan Fowler, Michael Dickinson, Joaquín Martínez‐López, Yucai Wang, Brian K. Link	2022	26
12	Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study Leukemia & lymphoma ·John Kuruvilla, Philippe Armand, Mehdi Hamadani, Justin Kline, Craig H. Moskowitz, David Avigan, Joshua Brody, Vincent Ribrag, Alex F. Herrera, Franck Morschhauser, Abraham S. Kanate, Pier Luigi Zinzani, Jacob D. Bitran, Hervé Ghesquières, Stephen J. Schuster, Mohammed Z.H. Farooqui, Patricia Marinello, Nancy L. Bartlett	2022	12
13	Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study Blood ·Nathan Fowler, Michael Dickinson, Monalisa Ghosh, Andy Chen, Charalambos Andreadis, Ranjan Tiwari, Aisha Masood, Roberto Ramos, Vamsi Bollu, Arezoo Avid, Catherine Thiéblemont, Martin Dreyling, Stephen J. Schuster	2021	4
14	Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study Blood ·Jia Ruan, Peter Martin, Paul J. Christos, Leandro Cerchietti, Bijal Shah, Stephen J. Schuster, Wayne Tam, Á Rodríguez, David M. Hyman, María Nieves Calvo Vidal, J. Park, Sonali M. Smith, Jakub Svoboda, Richard R. Furman, Morton Coleman, John P. Leonard	2017	7
15	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma Clinical Cancer Research ·Marco Ruella, Saad S. Kenderian, Olga Shestova, Joseph A. Fraietta, Sohail Qayyum, Qian Zhang, Marcela V. Maus, Xiaobin Liu, Selene Nuñez-Cruz, Michael Klichinsky, Omkar U. Kawalekar, Michael C. Milone, Simon F. Lacey, Anthony R. Mato, Stephen J. Schuster, Michael Kalos, Carl H. June, Saar Gill, Mariusz A. Wasik	2016	141
16	Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas Clinical Cancer Research ·Elise A. Chong, Tahamtan Ahmadi, Nicole A. Aqui, Jakub Svoboda, Sunita D. Nasta, Anthony R. Mato, Kristy M. Walsh, Stephen J. Schuster	2015	46
17	Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis British Journal of Haematology ·Christina Howlett, Sonya J. Snedecor, Daniel J. Landsburg, Jakub Svoboda, Elise A. Chong, Stephen J. Schuster, Sunita D. Nasta, Tatyana Feldman, Karol Julieth Vásquez Viafara, Kristy M. Walsh, Scott Weber, André Goy, Anthony R. Mato	2015	113
18	Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402 Journal of Clinical Oncology ·Brad S. Kahl, Fangxin Hong, Michael E. Williams, Randy D. Gascoyne, Lynne I. Wagner, John C. Krauss, Thomas M. Habermann, Lode J. Swinnen, Stephen J. Schuster, Christopher G. Peterson, Mark D. Sborov, Sabrina Martín, Matthias Weiss, W. Christopher Ehmann, Sandra J. Horning	2014	138
19	A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia Clinical Cancer Research ·Donald E. Tsai, Selina M. Luger, Charalambos Andreadis, Dan T. Vogl, Narcisa Naomi Chang-López, 民恵熊倉, Ami Goradia, Alison W. Loren, Alexander E. Perl, Stephen J. Schuster, David L. Porter, Edward A. Stadtmauer, Steven C. Goldstein, James E. Thompson, Cezary Swider, Adam Bagg, Anthony R. Mato, Martin Carroll	2008	29
20	Homocysteine and Prothrombin Fragment 1+2 Levels in Patients with Veno-Occlusive Disease after Stem Cell Transplantation Journal of Hematotherapy & Stem Cell Research ·John F. Gerecitano, Clarissa Mathias, Rosemarie Mick, Kathleen M. Duffy, Selina M. Luger, Edward A. Stadtmauer, Stephen J. Schuster, Donald E. Tsai, Sunita D. Nasta, Jesse A. Berlin, Bahattin Tunç, Katherine A. High, David L. Porter	2003	4

About Stephen J. Schuster

Stephen J. Schuster is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hematology and Dermatology, having authored 366 papers that have together received 11.7k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (212 papers), CAR-T cell therapy research (161 papers), Chronic Lymphocytic Leukemia Research (109 papers), Viral-associated cancers and disorders (39 papers), Cutaneous lymphoproliferative disorders research (24 papers), CNS Lymphoma Diagnosis and Treatment (22 papers), Multiple Myeloma Research and Treatments (22 papers) and Monoclonal and Polyclonal Antibodies Research (22 papers). The work is most often cited by research in Oncology (8.3k citations), Pathology and Forensic Medicine (4.7k citations), Genetics (2.0k citations), Immunology (2.9k citations) and Hematology (1.0k citations). Stephen J. Schuster has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Jakub Svoboda, Sunita D. Nasta, Elise A. Chong, Daniel J. Landsburg, Edward A. Stadtmauer, David L. Porter, Donald E. Tsai, Carl H. June, Simon F. Lacey and Philippe Armand. Their work appears in journals such as Blood, Journal of Clinical Oncology, American Journal of Hematology, Blood Advances and Hematological Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact